-
Frontiers in Public Health 2023Oxidative Balance Score (OBS) is an index affecting the oxidative stress of dietary and lifestyle factors. We aimed to explore the association of OBS with prostate...
OBJECTIVE
Oxidative Balance Score (OBS) is an index affecting the oxidative stress of dietary and lifestyle factors. We aimed to explore the association of OBS with prostate specific antigen (PSA) among older males.
METHODS
A total of 5,136 samples were collected in this study to investigate the relationship between OBS and PSA from the National Health and Nutrition Examination Survey. Logistic regression models and restricted cubic spline were used to assess the associations between OBS and PSA.
RESULTS
Compared with the Q1 group, the odds ratios for the association between OBS and PSA were 1.005 (1.003, 1.009), 1.003 (1.001, 1.006), and 1.001 (0.978, 1.022) for Q2, Q3, and Q4, respectively. In the age-specific analyses, the association was significant among individuals aged 65 years old and over: the odds ratios for the association between OBS and PSA were 1.019 (1.005, 1.028), 1.028 (1.018, 1.039), and 1.038 (1.022, 1.049) for Q2, Q3, and Q4, respectively. But it was not significant among individuals aged less than 65 years old: the odds ratios for the association between OBS and PSA were 1.016 (0.995, 1.026), 1.015 (0.985, 1.022), and 0.988 (0.978, 1.016) for Q2, Q3, and Q4, respectively. The restricted cubic splines also indicated a nonlinear relationship between OBS and PSA among individuals aged 65 years old and over ( = 0.006, = 0.021).
CONCLUSION
Our findings provide evidence that OBS is positively associated with higher levels of PSA among older adults. Further large-scale prospective cohort studies are needed to verify our findings.
Topics: Aged; Humans; Male; Middle Aged; Diet; Nutrition Surveys; Oxidative Stress; Prospective Studies; Prostate-Specific Antigen
PubMed: 38317687
DOI: 10.3389/fpubh.2023.1336657 -
European Urology Sep 2019The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostate cancer mortality after 16yr [rate ratio (RR) 0.80],... (Review)
Review
The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostate cancer mortality after 16yr [rate ratio (RR) 0.80], but centers varied by attendance, screen interval, biopsy compliance, contamination in the control arm, and treatments. We used a microsimulation model, calibrated to the ERSPC individual-level data, to predict influence of study features on the results. The relative reduction in prostate cancer mortality would have been somewhat larger with improved study features: increased attendance (90% attendance in all volunteer-based and 70% in all population-based centers, resulting in RR 0.77), a 2-yr screen interval (RR 0.75), and an 80% biopsy compliance (RR 0.79). The RR would have been substantially lower with a 30% attendance (RR 0.92), 40% biopsy compliance (RR 0.90), or 100% contamination (RR 0.85). The variations in results by trial center may reflect differences in study design and performance and results of our simulations highlight the effect of quality indicators in prostate-specific antigen screening in different settings. PATIENT SUMMARY: We evaluated the effect of various features of prostate-specific antigen (PSA) screening on its effectiveness. The compliance to PSA testing and those having a biopsy after an elevated PSA substantially influence the prostate cancer mortality.
Topics: Early Detection of Cancer; Europe; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 31031050
DOI: 10.1016/j.eururo.2019.04.007 -
The British Journal of General Practice... 2021Prostate cancer is a leading cause of cancer- related death. Interpreting the results from trials of screening with prostate-specific antigen (PSA) is complex in terms... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Prostate cancer is a leading cause of cancer- related death. Interpreting the results from trials of screening with prostate-specific antigen (PSA) is complex in terms of defining optimal prostate cancer screening policy.
AIM
To assess the rates of, and factors associated with, the uptake of PSA testing and opportunistic screening (that is, a PSA test in the absence of any symptoms) in England between 1998 and 2017, and to estimate the likely rates of pre-randomisation screening and contamination (that is, unscheduled screening in the 'control' arm) of the UK-based Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP).
DESIGN AND SETTING
Open cohort study of men in England aged 40-75 years at cohort entry (1998-2017), undertaken using the QResearch database.
METHOD
Eligible men were followed for up to 19 years. Rates of PSA testing and opportunistic PSA screening were calculated; Cox regression was used to estimate associations.
RESULTS
The cohort comprised 2 808 477 men, of whom 631 426 had a total of 1 720 855 PSA tests. The authors identified that 410 724 men had opportunistic PSA screening. Cumulative proportions of uptake of opportunistic screening in the cohort were 9.96% at 5 years', 22.71% at 10 years', and 44.13% at 19 years' follow-up. The potential rate of contamination in the CAP control arm was estimated at 24.50%.
CONCLUSION
A substantial number of men in England opt in to opportunistic prostate cancer screening, despite uncertainty regarding its efficacy and harms. The rate of opportunistic prostate cancer screening in the population is likely to have contaminated the CAP trial, making it difficult to interpret the results.
Topics: Adult; Aged; Cohort Studies; Early Detection of Cancer; England; Humans; Male; Mass Screening; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 33431381
DOI: 10.3399/bjgp20X713957 -
International Journal of Environmental... May 2023There is limited research about the content and context of communication on prostate-specific antigen (PSA) testing among men in the state of Florida. The purpose of...
There is limited research about the content and context of communication on prostate-specific antigen (PSA) testing among men in the state of Florida. The purpose of this study is to understand how the content communication (discussion of advantages and disadvantages of PSA testing between provider and patient; provider recommendations of PSA testing) and the context of communication (continuity of care denoted by the presence of a personal doctor) influence PSA testing. Data were drawn from the Florida Behavioral Risk Factor Surveillance System. Receipt of PSA testing was the primary outcome. Multiple logistic regression analyses were used to adjust for sociodemographic, clinical, healthcare access, and lifestyle characteristics when associating the content and context of communication with PSA testing. Discussions were classified into four mutually exclusive categories: discussions of advantages and disadvantages, only advantages, only disadvantages, and no discussion. The most significant predictors for PSA testing included physician recommendation, discussions including advantages, older age, non-smoking, and having a personal doctor. Individualized PSA screening may be a pathway to reducing racial disparities in screening for prostate cancer (PCa) and, by extension, lower incidence and mortality rates. Developing a bill to create an Office of Men's Health at Health & Human Services is recommended.
Topics: Male; Humans; Prostate-Specific Antigen; Mass Screening; Decision Making; Prostatic Neoplasms; Communication; Early Detection of Cancer
PubMed: 37174239
DOI: 10.3390/ijerph20095721 -
Cleveland Clinic Journal of Medicine May 2021
Topics: Early Detection of Cancer; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms; United Kingdom
PubMed: 33941594
DOI: 10.3949/ccjm.88c.05001 -
Cleveland Clinic Journal of Medicine May 2021
Topics: Early Detection of Cancer; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms; United Kingdom
PubMed: 33941595
DOI: 10.3949/ccjm.88c.05002 -
BMC Urology Sep 2021Only a few previous studies conducted to assess the association between body mass index (BMI) and prostate-specific antigen (PSA) related parameters have taken prostate...
BACKGROUND
Only a few previous studies conducted to assess the association between body mass index (BMI) and prostate-specific antigen (PSA) related parameters have taken prostate volume (PV) and blood volume (BV) into consideration. The objective of this study was to assess the relationship between BMI and parameters of PSA concentrations in Chinese adult men.
METHODS
A total of 86,912 men who have received annual physical examination at the First Affiliated Hospital of Army Medical University from 1 January 2011 to 31 December 2018 were included in this study. Linear regression models were performed to assess the relationship between BMI, PV, BV and PSA, and analyze the correlation between BMI and PSA, PSA density and PSA mass.
RESULTS
The univariable linear regression showed that PV, BV, systolic pressure (SBP), pulse, fasting blood glucose (FBG) and age were significantly associated with PSA level (P < 0.05). The multivariate linear regression demonstrated that PV, BV, FBG and age were significantly associated with PSA level (P < 0.05). WHR and BMI is negatively associated with PSA and PSA density (P < 0.05), and no statistically significant association was found between PSA mass and WHR and (P = 0.268) or BMI (P = 0.608).
CONCLUSIONS
The findings of this large-sample, hospital-based study in China indicate that PV was positively associated with serum PSA concentrations, while BMI and BV were inversely related with PSA levels. PSA mass can be used to estimate the PSA concentration without being affected by obesity in Chinese men.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Blood Volume; Body Mass Index; China; Cross-Sectional Studies; Humans; Linear Models; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Young Adult
PubMed: 34530776
DOI: 10.1186/s12894-020-00746-8 -
Andrology Sep 2020Serum testosterone assays are an important tool in the clinical evaluation of a number of endocrine disorders including male hypogonadism. However, serum testosterone... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Serum testosterone assays are an important tool in the clinical evaluation of a number of endocrine disorders including male hypogonadism. However, serum testosterone has a limited role in real clinical use due to its inaccuracy. We aimed to assess the association between prostate-specific antigen (PSA) and testosterone as well as the effects of various types of testosterone replacement therapy (TRT) for PSA level.
METHODS
Two electronic databases were screened: PubMed (1966 through December 2018) and Cochrane Library (1993 through December 2018). The first strategy compared the overall increase in PSA following testosterone treatment compared with placebo. The second strategy analyzed the overall association between PSA and testosterone among the observational studies.
RESULTS
In the first strategy, 22 articles were included in the final analysis. In the second strategy, 18 studies were included. Testosterone replacement therapy (TRT) showed a significant change in PSA level compared to that in the placebo group (mean difference [MD]: 0.13, 95% CI: 0.01-0.25, P = .04). Compared to placebo, only intramuscular (IM) TRT shows a significant change in PSA level group (MD: 0.16, 95% CI: 0.01-0.30, P = .04), as neither the oral nor topical type showed a significant change in PSA. In the second strategy analysis, there was no overall correlation found between PSA and testosterone (z = 0.04, 95% CI: -0.04 to 0.12, P = .04; r = 0.039). However, in the subgroup of non-BPH (benign prostate hyperplasia), a significant correlation between PSA and testosterone (z = 0.07, 95% CI: 0.01-0.13, P = .009; r = 0.089) was found.
CONCLUSIONS
We found that TRT, particularly IM TRT, significantly changed the PSA level compared with the placebo group. Furthermore, there was a significant correlation between PSA and testosterone in patients with non-BPH. According to these findings, we suggest the possibility of PSA as a surrogate marker of testosterone.
Topics: Biomarkers; Hormone Replacement Therapy; Humans; Male; Prostate-Specific Antigen; Testosterone
PubMed: 32329181
DOI: 10.1111/andr.12806 -
High-throughput glycopeptide profiling of prostate-specific antigen from seminal plasma by MALDI-MS.Talanta Jan 2021An altered total seminal plasma glycosylation has been associated with male infertility, and the highly abundant seminal plasma glycoprotein prostate-specific antigen...
An altered total seminal plasma glycosylation has been associated with male infertility, and the highly abundant seminal plasma glycoprotein prostate-specific antigen (PSA) plays an important role in fertilization. However, the exact role of PSA glycosylation in male fertility is not clear. To understand the involvement of PSA glycosylation in the fertilization process, analytical methods are required to study the glycosylation of PSA from seminal plasma with a high glycoform resolution and in a protein-specific manner. In this study, we developed a novel, high-throughput PSA glycopeptide workflow, based on matrix-assisted laser desorption/ionization-mass spectrometry, allowing the discrimination of sialic acid linkage isomers via the derivatization of glycopeptides. The method was successfully applied on a cohort consisting of seminal plasma from infertile and fertile men (N = 102). Forty-four glycopeptides were quantified in all samples, showing mainly complex-type glycans with high levels of fucosylation and sialylation. In addition, N,N-diacetyllactosamine (LacdiNAc) motives were found as well as hybrid-type and high mannose-type structures. Our method showed a high intra- and interday repeatability and revealed no difference in PSA glycosylation between fertile and infertile men. Next to seminal plasma, the method is also expected to be of use for studying PSA glycopeptides derived from other biofluids and/or in other disease contexts.
Topics: Glycopeptides; Glycosylation; Humans; Male; Polysaccharides; Prostate-Specific Antigen; Semen; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
PubMed: 33167210
DOI: 10.1016/j.talanta.2020.121495 -
International Journal of Cancer Dec 2020This review discusses evidence for population-based screening with contemporary screening tools. In Europe, prostate-specific antigen (PSA)-based screening led to a... (Review)
Review
This review discusses evidence for population-based screening with contemporary screening tools. In Europe, prostate-specific antigen (PSA)-based screening led to a relative reduction of prostate cancer (PCa) mortality, but also to a substantial amount of overdiagnosis and unnecessarily biopsies. Risk stratification based on a single variable (a clinical variable or based on the presence of a lesion on prostate imaging) or based on multivariable approaches can aid in reducing unnecessary prostate biopsies and overdiagnosis by selecting men who can benefit from further clinical assessment. Multivariable approaches include clinical variables, and biomarkers, often combined in risk calculators or nomograms. These risk calculators can also incorporate the result of MRI imaging. In general, as compared to a purely PSA based approach, the combination of relevant prebiopsy information results in superior selection of men at higher risk of harboring clinically significant prostate cancer. Currently, it is not possible to draw any conclusions on the superiority of these multivariable risk-based approaches since head-to-head comparisons are virtually lacking. Recently initiated large population-based screening studies in Finland, Germany and Sweden, incorporating various multivariable risk stratification approaches will hopefully give more insight in whether the harm-benefit ratio can be improved, that is, maintain (or improving) the ability to reduce metastatic disease and prostate cancer mortality while reducing harm caused by unnecessary testing and overdiagnosis including related overtreatment.
Topics: Early Detection of Cancer; Humans; Magnetic Resonance Imaging; Male; Multivariate Analysis; Precision Medicine; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment
PubMed: 32394421
DOI: 10.1002/ijc.33045